Follow Insulet to never miss an important update.
On September 21, Insulet updated its credit agreement to lower the interest rates it pays on its debt. The company replaced $475 million in existing loans with new ones that carry an interest rate 0.25% lower than before. It also increased its revolving credit line, a flexible pool of money it can borrow from as needed, by $250 million, bringing the total available to $750 million.
This move is a sign of financial health. Lenders often agree to lower rates when a company's business has become more stable or profitable, and the extra credit gives Insulet more room to fund its growth. For a company plowing cash into high-volume manufacturing for its Omnipod system, having cheaper and more flexible access to cash is a clear win.
Source: 8-K filing
On September 14, the board approved a new plan that allows a group of senior managers and executives to defer up to 60 percent of their cash pay, including base salary and bonuses. This type of plan is a common tool for high-earning employees to manage their taxes by choosing when they actually receive their income, often waiting until they retire or leave the company. The plan takes effect on January 1, 2027. While it allows the company to match some of these contributions, the primary purpose is to help attract and keep senior talent. For long-term owners, this is a routine administrative update to how the company handles executive pay and does not change the outlook for the business.
Source: 8-K filing
Insulet announced that two of its directors are stepping down this month. Timothy Scannell, who served on the board for 12 years and was Chairman for seven, left his post on September 3 for health reasons. Michael Minogue is also leaving on September 15 to focus on his run for Governor of Massachusetts after nine years with the company.
While losing two experienced directors at once is a change in leadership, both departures appear orderly and are for personal reasons rather than disagreements with the company. For a long-term owner, this is a routine transition for a board that oversaw the company's growth into a multibillion-dollar business, and it does not change the outlook for its insulin pump technology.
Source: 8-K filing
CEO Ashley McEvoy purchased roughly $162,000 worth of shares on Friday. Unlike the routine stock awards or scheduled sales that make up most insider activity, this was an open-market purchase using her own cash.
When a leader buys their own stock this way, it is often a signal that they believe the current price is too low. For a company like Insulet, which is working to expand its wearable insulin pumps into the much larger market for people with type 2 diabetes, this kind of personal commitment from the top is a positive sign for long-term owners.
Robbins LLP has filed a securities class action lawsuit on behalf of people who bought the stock between February 2025 and May 2026. The suit claims the company made misleading statements about its manufacturing controls and how safe its insulin pumps were during that time. These types of lawsuits are common when a stock price drops, as law firms look for shareholders to lead a case for damages. While the claims focus on product reliability, they rarely impact the day-to-day operations of the business unless they lead to a major fine or reveal a deep flaw in the product that was previously unknown.
Source: GlobeNewsWire
Management consistently sets a bar they can clear, beating expectations for eight straight quarters as the business outruns even the most optimistic forecasts.
| Expectation | |
|---|---|
| EPS | $1.59 |
| Revenue | $833M |